|Bid||109.00 x 12100|
|Ask||110.00 x 11600|
|Day's Range||110.00 - 111.00|
|52 Week Range||71.44 - 125.00|
|Beta (3Y Monthly)||0.19|
|PE Ratio (TTM)||119.35|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Blood management firm Haemonetics is pulling back to a support level, which could potentially provide investors with a new buying opportunity.
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of June 28. In this […]
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
President & CEO of Haemonetics Corp (NYSE:HAE) Christopher Simon, sold 5,008 shares of HAE on 07/01/2019 at an average price of $121.79 a share.
President & CEO of Haemonetics Corp (NYSE:HAE) Christopher Simon, sold 57,587 shares of HAE on 05/13/2019 at an average price of $94.51 a share.
The Braintree, Massachusetts-based company said it had profit of 40 cents per share. Earnings, adjusted for one-time gains and costs, came to 61 cents per share. The results beat Wall Street expectations. ...
On a per-share basis, the Braintree, Massachusetts-based company said it had net income of 35 cents. Earnings, adjusted for non-recurring costs and amortization costs, were 63 cents per share. The results ...
Haemonetics (HAE) sees encouraging growth at the North America Plasma revenues on strong disposables along with growing software revenues.
Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
On a per-share basis, the Braintree, Massachusetts-based company said it had profit of 35 cents. Earnings, adjusted for one-time gains and costs, came to 56 cents per share. The results exceeded Wall Street ...